MedTrace Logo

Oligomeric Alpha-synuclein in Multiple System Atrophy

NCT01485549 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2019-06-27

No results posted yet for this study

Summary

The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF) and plasma levels.

Conditions

  • Multiple System Atrophy (MSA)

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Wassilios MEISSNER, MD, PhD · University Hospital, Bordeaux

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-26
Primary Completion
2018-11-20
Completion
2018-11-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01485549 on ClinicalTrials.gov